SequelSEC

CASTLE BIOSCIENCES INC CSTL

Services-Medical Laboratories · CIK 0001447362 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$357.28M
Fiscal year ended 2026-06-30
Operating income
-$32.11M
Fiscal year ended 2026-06-30
Free cash flow
-$489.00K
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$576.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$19.37Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity0.02x0th
Gross margin79.4%100th
CapEx / revenue10.5%82th
Revenue YoY growth3.7%20th
FCF margin8.2%76th
SBC / revenue13.3%70th
Current ratio5.26x64th
R&D / revenue15.1%38th
Net margin-7.0%62th
Operating margin-12.4%62th

CASTLE BIOSCIENCES INC (CSTL) reported revenue of $357.28M and net income of -$19.42M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CASTLE BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

CASTLE BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$357.28M
Cost of revenue$81.25M
Gross profit$276.03M
Operating income-$32.11M
Net income-$19.42M
Research & development$55.45M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$212.00K
Diluted EPSUnavailable
Selling, general & administrative$243.66M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

CASTLE BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$62.12M
Total assets$561.18M
Current assets$341.10M
Total liabilities$91.15M
Current liabilities$56.51M
Total equity incl. NCI$470.03M
Temporary (mezzanine) equityUnavailable
Inventory$10.58M
Accounts receivable$48.34M
Goodwill$10.70M
Long-term debt$7.16M
Accounts payable$9.67M

Cash flow

CASTLE BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$42.63M
Capital expenditures$43.12M
Investing cash flow-$51.32M
Financing cash flow-$11.43M
Net change in cash-$20.12M
Stock-based compensation$44.87M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$15.59M

Derived

CASTLE BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$489.00K
Gross margin77.3%
Operating margin-9.0%
FCF margin-0.1%
SBC / revenue12.6%
Current ratio6.04x
Revenue YoY growth3.2%
Net margin-5.4%
R&D / revenue15.5%
CapEx / revenue12.1%
Long-term debt / equity0.02x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CSTL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BGLC BLLN CAI CDNA CELC CFOR DGX FCHS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.